G protein-coupled receptors (GPCRs) are membrane-bound signaling proteins that play an important role in clinical medicine. Mutations in GPCRs have been implicated in a variety of human diseases and they constitute the largest class of protein targets for pharmacological manipulation. However, technical challenges persist in the rapid screening of GPCR agonists and antagonists. The Scientist brings together a panel of experts to discuss advances in high-throughput screening for GPCR drug discovery. Attendees will have an opportunity to interact with the experts, ask questions, and seek advice on topics related to their drug discovery research.
Dr. Edward Ainscow, Director
Genomics Institute of the Novartis Research Foundation
Sylvie Jezequel-Sur, MS Associate Principal Scientist
Merck & Co.
R. Jason Kirby, MS Senior Associate Scientist
Sanford Burnham Prebys Medical Discovery Institute